Product News

Share this article:

UCB received FDA approval on a new indication for Cimzia, an injectable tumor necrosis factor (TNF) blocker. Cimzia is now indicated for moderate to severe rheumatoid arthritis, in addition to its prior indication for Crohn's disease. Cimzia will compete other TNF blockbusters such as Abbott's Humira, Johnson & Johnson's Remicade and Wyeth/Amgen's Enbrel.

 

Takeda received an FDA nod for an extended release version of its combo med Actoplus Met: Actoplus Met XR. Actoplus Met and Actoplus Met XR are indicated for the treatment of type 2 diabetes.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.